IFNB1 and myeloid sarcoma: Since previous studies indicated that patients with MS that are treated with IFNb exhibit marked increases in serum IL-27 [16], we determined whether the mDCs from the IFNb-treated patients differed from those isolated from patients that were not receiving any treatment.